Wegovy users have five times greater risk of sudden sight loss than Ozempic users, study finds
‘Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says authorPatients taking Wegovy have nearly five times the risk of sudden sight loss of those on Ozempic, a large-scale study has found.Glucagon-like peptide-1 receptor agonist...
<p>‘Eye strokes’ that reduce blood flow to optic nerve likely to be side-effect of active ingredient semaglutide, says author</p><p>Patients taking Wegovy have nearly five times the risk of sudden sight loss of those on Ozempic, <a href="https://bjo.bmj.com/lookup/doi/10.1136/bjo-2025-328483">a large-scale study</a> has found.</p><p>Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medicines such as semaglutide (sold as Wegovy, Ozempic and Rybelsus) and tirzepetide (sold as Mounjaro) help reduce blood sugar levels, slow digestion and reduce appetite, and have been linked to <a href="https://www.theguardian.com/science/2025/oct/22/weight-loss-drug-cuts-heart-attack-risk-no-matter-how-many-kgs-are-shed-study-finds">reduced risks of heart attack</a>, <a href="https://www.theguardian.com/science/2026/mar/04/weight-loss-addiction-drugs-alcohol-study">fewer drug overdoses</a> and other health benefits.</p> <a href="https://www.theguardian.com/society/2026/mar/10/wegovy-sudden-sight-loss-ozempic-study-semaglutide">Continue reading...</a>
Read the full article at:
The Guardian World →